Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 20,890 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Non-treatment Clear all
Recruiting Phase 2 Interventional

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

NCT07023835
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
50 mg Usnoflast, 75 mg Usnoflast, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
La Jolla, California • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 24, 2026, 6:53 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT03052608
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lorlatinib, Crizotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
34
States / cities
Altamonte Springs, Florida • Brandon, Florida • Clearwater, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 24, 2026, 6:53 AM EDT
Not listed Phase 4 Interventional

Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion

NCT04502017
View directory record Official record
Conditions
Device-Related Thrombosis, Atrial Fibrillation, Left Atrial Appendage Occlusion
Interventions
ASA plus Clopidogrel, Genetic-Tailored AntiThrombotic Strategy, Half-Dose of novel OAC
Drug
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 24, 2026, 6:53 AM EDT
Terminated Phase 4 Interventional Results available

Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

NCT03471117
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Pioglitazone, Placebo
Drug · Other
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
35 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Arlington, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 24, 2026, 6:53 AM EDT
Terminated Phase 2 Interventional

The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis

NCT00646425
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
Basiliximab, Placebo
Drug
Lead sponsor
Cerimon Pharmaceuticals
Industry
Eligibility
12 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Cambridge, Massachusetts • Kansas City, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2010 · Synced Oct 24, 2026, 6:53 AM EDT
Active, not recruiting Not applicable Interventional

Proton Craniospinal Irradiation With Bone Sparing to Decrease Growth Decrement From Radiation

NCT03281889
View directory record Official record
Conditions
Brain Tumor
Interventions
Proton Beam
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
3 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 24, 2026, 6:53 AM EDT
Completed Phase 4 Interventional

OnabotulinumtoxinA in the Management of Psychogenic Dystonia

NCT02618889
View directory record Official record
Conditions
Torticollis, Dystonia
Interventions
CBT
Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 24, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
53
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 24, 2026, 6:53 AM EDT
Not listed Not applicable Interventional

A Prospective, Randomized Clinical Trial of PRP Concepts Fibrin Bio-Matrix in Chronic Non-Healing Venous Leg Ulcers

NCT02312518
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
PRP Concepts Fibrin Bio-Matrix, Usual and Customary Practice
Device · Other
Lead sponsor
PRP Concepts, LLC
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 24, 2026, 6:53 AM EDT
Terminated Phase 2 Interventional

Tezosentan in Pulmonary Arterial Hypertension

NCT01077297
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Tezosentan
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 24, 2026, 6:53 AM EDT
Withdrawn Phase 2 Interventional

Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer

NCT01700010
View directory record Official record
Conditions
Urothelial Cancer, Bladder Cancer
Interventions
Lapatinib and Paclitaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 24, 2026, 6:53 AM EDT
Terminated Phase 2 Interventional Results available

Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma

NCT02420210
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Bendamustine Hydrochloride, Obinutuzumab, Dexamethasone, Quality-of-Life Assessment, Laboratory Biomarker Analysis
Drug · Biological · Other
Lead sponsor
University of Chicago
Other
Eligibility
70 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 24, 2026, 6:53 AM EDT
Terminated Phase 2 Interventional Results available

Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19

NCT05124210
View directory record Official record
Conditions
COVID-19
Interventions
Sotrovimab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
0 Days to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Cullman, Alabama • Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 24, 2026, 6:53 AM EDT
Terminated Not applicable Interventional Results available

Telehealth Based Synchronous Navigation to Improve Molecularly-Informed Care for Patients With Lung Cancer

NCT05790460
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Telehealth
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 24, 2026, 6:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

NCT02805660
View directory record Official record
Conditions
Advanced Cancer
Interventions
Mocetinostat - 50 mg, Mocetinostat - 70 mg, Mocetinostat - 90 mg, Mocetinostat - Recommended Phase 2 Dose (70 mg), Durvalumab - 1500 mg
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
15
States / cities
Mobile, Alabama • Los Angeles, California • Pensacola, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 24, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

NCT00194779
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
doxorubicin hydrochloride, cyclophosphamide, paclitaxel, filgrastim, capecitabine, methotrexate, vinorelbine tartrate, needle biopsy, therapeutic conventional surgery, immunohistochemistry staining method, trastuzumab, tamoxifen citrate, letrozole, laboratory biomarker analysis
Drug · Biological · Procedure + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 24, 2026, 6:53 AM EDT
Recruiting Phase 2 Interventional

PH 2 Pemigatinib in SDH-deficient GIST

NCT07434843
View directory record Official record
Conditions
SDH Gene Mutation, Gastrointestinal Stromal Tumor
Interventions
Pemigatinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 24, 2026, 6:53 AM EDT
Completed Not applicable Interventional

Acupuncture and Post-Operative Ileus

NCT00655317
View directory record Official record
Conditions
Ileus
Interventions
Acupuncture, Sham acupuncture
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 24, 2026, 6:53 AM EDT
Completed Not applicable Interventional Results available

Digital Knee Osteoarthritis Mindset Intervention

NCT05698368
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Mindset intervention, Active comparator
Behavioral · Other
Lead sponsor
Stanford University
Other
Eligibility
45 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 24, 2026, 6:53 AM EDT
Recruiting Not applicable Interventional

Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy

NCT06300450
View directory record Official record
Conditions
Peripheral Artery Disease, Peripheral Vascular Diseases, Dyslipidemias
Interventions
Computer Alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 24, 2026, 6:53 AM EDT
Recruiting Not applicable Interventional

Brief Digitally-Enhanced Intervention for Reducing Alcohol Use During MOUD

NCT06718491
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Managing Physical Reactions to Overwhelming Emotions (IMPROVE), Health Education Training (HET)
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 24, 2026, 6:53 AM EDT
Completed Not applicable Interventional

Psychological Intervention Mobile App for Patients With AML

NCT03372291
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Usual Care, Psychological intervention
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 24, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer

NCT01769391
View directory record Official record
Conditions
Squamous Non Small Cell Lung Cancer
Interventions
Necitumumab, Paclitaxel, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
33
States / cities
Jonesboro, Arkansas • Los Angeles, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 24, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

NCT00413218
View directory record Official record
Conditions
Candidiasis, Invasive, Candidemia, Mycoses
Interventions
Isavuconazole, Caspofungin, Voriconazole
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
18
States / cities
Birmingham, Alabama • Palm Desert, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 24, 2026, 6:53 AM EDT